e-Drug3D

1797

cas 61-73-4

CLASS

TREATMENT OF METHEMOGLOBINEMIA
AN OXIDATION-REDUCTION AGENT
PROMOTES A NON-ENYZMATIC REDOX CONVERSION OF METHB TO HEMOGLOBIN
CONVERTED INTO LEUCOMETHYLENE BLUE (LMB) BY NADPH REDUCTASE

ROUTE (list)

INTRAVENOUS

PK parameters

VD 255 LITER
PPB 94 PERCENT
t1/2 24 HOUR

TARGET NADPH REDUCTASE

PDB
5DLP (ACETYCHOLINESTERASE METHYLENE BLUE NO PEG)

Ligand code = MBT (link to the list of PDB complexes)

Download experimental 3D coordinates of MBT with added hydrogens

MW 284.40
NB_atoms 20
XLogP 3.86
PSA 16.179
NB_HD 0
NB_HA 3
fsp3 0.25
Lipinski(0=no;1=yes) 1

FDA
NDA 204630 (pdf not found) INN (METHYLENE BLUE) PROVAYBLUE (PROVEPHARM SAS) APPROVAL= AP YEAR= 2016
NDA 215636 (pdf not found) INN (METHYLENE BLUE) METHYLENE BLUE (ZYDUS LIFESCIENCES) APPROVAL= AP YEAR= 2023
NDA 216955 (pdf not found) INN (METHYLENE BLUE) METHYLENE BLUE (STERISCIENCE) APPROVAL= AP YEAR= 2024
NDA 216959 (pdf not found) INN (METHYLENE BLUE) METHYLENE BLUE (HIKMA) APPROVAL= AP YEAR= 2024
NDA 217561 (pdf not found) INN (METHYLENE BLUE) METHYLENE BLUE (NEXUS) APPROVAL= AP YEAR= 2024
NDA 217380 (pdf not found) INN (METHYLENE BLUE) METHYLENE BLUE (MEITHEAL) APPROVAL= AP YEAR= 2025
NDA 219363 (pdf not found) INN (METHYLENE BLUE) METHYLENE BLUE (XIROMED) APPROVAL= AP YEAR= 2025